Exploratory Trial of Immunochemoradiotherapy for Locally Advanced Pancreatic Adenocarcinoma
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Sponsor
- Providence Health & Services
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Safety
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger study is warranted.
Detailed Description
All study participants receive an initial 4 week course of intra-dermal vaccination with telomerase vaccine (GV1001) and immune adjuvant, granulocyte macrophage colony-stimulating factor (GM-CSF), along with a cycle of gemcitabine chemotherapy. This is followed by concurrent radiation therapy and low-dose intravenous (IV) gemcitabine chemotherapy given twice weekly followed by one additional dose of vaccine. About 4 weeks (as late as 8 weeks) after chemotherapy and radiation treatment, participants with disease that can be removed by surgery will proceed to surgery. After recovery, immunochemotherapy will resume. Participants with stable or responsive disease that is not able to be treated with surgery will proceed to immunochemotherapy. Immunochemotherapy will consist of 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine chemotherapy. Participants with disease that is not able to be treated with surgery, or that has worsened following immunochemoradiotherapy phase of treatment may continue on study with transition to immunochemotherapy phase of treatment. Tadalafil will be administered orally on a daily basis from start of therapy (Day 1) through completion of therapy with doses held only when required in the immediate perioperative period in patients who proceed to surgery.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pancreatic adenocarcinoma proven by biopsy or cytology Locally advanced, unresectable disease with absence of distant metastatic disease. The presence of non-regional retroperitoneal or abdominal adenopathy is acceptable for inclusion.
- •Borderline resectable pancreatic adenocarcinoma (any of the following):
- •Tumor abutment or encasement of a short segment of hepatic artery (without evidence of tumor extension to the celiac artery) that is amenable to resection and reconstruction
- •Tumor abutment of the superior mesenteric artery involving 180 degrees or less of the circumference of the artery and without encasement
- •Impingement or narrowing of the superior mesenteric vein/portal vein or short-segment (\< 2 cm) occlusion of the superior mesenteric vein, portal vein, or their confluence with a suitable option for vascular reconstruction
- •Eastern Cooperative Oncology Group(ECOG)Performance Status 0 or 1
- •Ability to give informed consent and comply with the protocol
- •Women of childbearing potential must have a negative pregnancy test and must avoid becoming pregnant while on treatment. Men must avoid fathering a child while on treatment.
- •Patients with a history of psychiatric illness must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.
Exclusion Criteria
- •Age \< 18 years
- •History of other malignancy in the past 2 years except carcinoma in situ of the cervix or bladder, or non-melanomatous skin cancer
- •Previous chemotherapy or radiation therapy for pancreatic cancer or previous radiation therapy to the target field
- •Clinically active autoimmune disease or active infection
- •History of heart attack (within 90 days) or stroke (within 6 months), or presence of hypertension requiring change in blood pressure medications in the last 4 weeks, hypotension, uncontrolled arrhythmias, heart failure (New York Heart Association (NYHA) Functional Classification ≥ Class 2 in last 6 months), unstable angina or angina occurring during sexual activity.
- •Use of "nitrates" or nitroglycerin.
- •History of hereditary degenerative retinal disorders including retinitis pigmentosa.
- •Chronic systemic corticosteroid use at supra-physiologic doses (prednisone \> 10 mg a day or equivalent)
- •Use of recreational drugs called "poppers" like amyl nitrite and butyl nitrite.
- •Laboratory values (performed within 14 days prior to enrollment) as follows:
Outcomes
Primary Outcomes
Safety
Time Frame: 180 Days
Adverse events will be graded no less than weekly for the first 180 days. Post-treatment long-term follow-up will occur every 12 weeks beyond day 180 for 6 visits and then every 24 weeks thereafter until progressive disease, withdrawal from study or death. For this pilot study, adverse events and efficacy measures will be personally reviewed by the principal investigator. Both hematologic and non-hematologic toxicity will be anticipated. In conjunction with the IRB, stopping the trial will be among possible measures taken if undue toxicity or inadequate outcomes are observed.
Secondary Outcomes
- Tumor Response(180 days)
- Immune Response(18 months)